Low Molecular Weight Heparin Market Segmentation Application, Technology & Market Analysis Report by 2025

Google+ Pinterest LinkedIn Tumblr +

Low Molecular Weight Heparins (LMWH) are a form of pharmacological anticoagulant intervention. Low molecular weight heparin is used for prophylaxis of deep vein thrombosis and pulmonary embolism, or thrombosis occurring in a broad spectrum of clinical indications, including general or orthopaedic surgery, neurosurgery, trauma, unstable angina, and myocardial infarction. LMWHs are derived from UFH by chemical or enzymatic depolymerisation to yield fragments that are around one third the size of heparin.  However, it is associated with higher anticoagulant effect and provides higher bioavailability after subcutaneous administration, as compared to unfractionated heparin (UFH), for thromboembolic indications. Low molecular weight heparin is the most suitable anticoagulant in case of complicated pregnancy, as it eliminates risk of crossing the placental membrane.

Request to download and view Sample Report: https://www.coherentmarketinsights.com/insight/request-sample/1491

Low Molecular Weight Heparin Market Driver

Low molecular weight heparin market growth attributed to advantages of low molecular weight heparin over unfractionated heparin. Unfractionated heparin or standard heparin varies in action from patient to patient. Thus, it can only be administered by hospitalized patients under monitoring, while low molecular weight heparin can be used subcutaneously once a day,  without the need for monitoring. Furthermore, heparin is associated with serious side-effects such as Thrombocytopenia, heparin-induced thrombocytopenia (HIT), and heparin-induced thrombocytopenia and thrombosis (HITT). Such advantages of low molecular weight heparin over unfractionated heparin is boosting growth of the low molecular weight heparin market. Additionally, properties such as better bioavailability, predictable dose response, and longer plasma half-life than unfractionated heparin, makes low molecular weight heparin a better candidate for anticoagulant therapy. This in turn, is fuelling demand for low molecular weight heparin, thus expected to boost market growth over the forecast period (2017 – 2025).

Increasing inclination of research institutes towards developing novel alternatives for available LMWH treatments is expected to widen the range of therapies, while narrowing down its side effects. For example, American University of Beirut Medical Centre sponsored the study for a drug, bemiparin sodium (a form of LMWH), which is in phase 4 and is expected to be completed in mid-2018, to improve the pregnancy outcomes in patients with recurrent implantation failure undergoing IVF/ ICSI treatment. Additionally, companies are collaborating with hospitals to strengthen their product portfolio. For instance, Bayer in collaboration with Assistance Publique – Hopitaux de Paris is studying combination of rivaroxaban and low molecular weight heparin for neoplasm and venous thromboembolism, which is in phase 3. Both these pipeline drugs are expected to complete their final stages of study during the forecast period, which in turn is expected to enhance the low molecular weight heparin market.

Low molecular weight heparin is approved for the treatment of prophylaxis and orthopaedic surgeries, deep vein thrombosis, unstable angina, and complicated pregnancies. Thus, growing prevalence of these conditions is expected to increase demand for low molecular weight heparin market. For instance, according to Centers for Disease Control and Prevention (CDC, 2015), 900,000 people are affected by venous thromboembolism, each year in the U.S. Furthermore, 5% to 8% of the U.S. population has increased risk for thrombosis due to one of several genetic risk factors known as inherited thrombophilia. Thus, increasing demand for low molecular weight heparin in surgeries and for treating blood clotting disorders in turn, is expected to boost growth of the low molecular weight heparin market.

Request to download and view full ToC: https://www.coherentmarketinsights.com/ongoing-insight/toc/1491

Low Molecular Weight Heparin Market – Competitors

Key player operating in the low molecular weight heparin market include Sanofi, Amphastar Pharmaceutical Inc., Teva Pharmaceuticals Industries Inc., Pfizer, Inc., LEO Pharmaceutical Products, Celgene Corporation, Sandoz GmbH (a division of Novartis AG), and Changzhou Qianhong Bio-pharma co. ltd.

Share.

About Author

Is a technology enthusiast, who has amassed a wide range of experience in the industry at a very young age. His extensive background of computer software and programming and proclivity to be up-to-date with the latest of technology upgrades and launches, helps him deliver the most intriguing and trending tech news. Contact Author

Comments are closed.